Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 4,983 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 4,983 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $108.37, for a total value of $540,007.71. Following the transaction, the chief financial officer now directly owns 75,059 shares in the company, valued at approximately $8,134,143.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, May 1st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $93.97, for a total value of $175,348.02.
• On Monday, April 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $93.14, for a total value of $115,307.32.
• On Thursday, April 25th, Michael Burkes Brophy sold 705 shares of Natera stock. The shares were sold at an average price of $89.55, for a total value of $63,132.75.
• On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The shares were sold at an average price of $91.38, for a total value of $139,171.74.

Natera Stock Performance

NASDAQ NTRA opened at $110.70 on Wednesday. The firm has a market capitalization of $13.59 billion, a P/E ratio of -35.48 and a beta of 1.48. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $117.23. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.12 and a quick ratio of 3.98. The business’s 50-day simple moving average is $105.29 and its 200-day simple moving average is $86.70.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.16. The business had revenue of $367.70 million for the quarter, compared to analyst estimates of $316.31 million. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The company’s revenue was up 52.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.23) EPS. Equities analysts predict that Natera, Inc. will post -2.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on NTRA shares. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. Robert W. Baird increased their price objective on Natera from $99.00 to $117.00 and gave the company an “outperform” rating in a research note on Friday, May 10th. Jefferies Financial Group started coverage on Natera in a research note on Monday, June 3rd. They set a “buy” rating and a $142.00 price objective on the stock. Piper Sandler increased their price objective on Natera from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Tuesday, May 14th. Finally, TD Cowen increased their price objective on Natera from $123.00 to $137.00 and gave the company a “buy” rating in a research note on Friday, May 10th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $101.19.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently modified their holdings of the company. RiverPark Advisors LLC purchased a new stake in shares of Natera during the 4th quarter valued at about $27,000. Principal Securities Inc. purchased a new stake in shares of Natera during the 4th quarter valued at about $32,000. GAMMA Investing LLC raised its holdings in shares of Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after buying an additional 108 shares during the period. YHB Investment Advisors Inc. purchased a new stake in shares of Natera during the 1st quarter valued at about $36,000. Finally, Oliver Lagore Vanvalin Investment Group raised its holdings in shares of Natera by 109.3% during the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after buying an additional 389 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.